Épisodes

  • In the News... Universal T1D screening studied, Dexcom new product, Afrezza prescribing guidelines update, and more!

    In the News... Universal T1D screening studied, Dexcom new product, Afrezza prescribing guidelines update, and more!
    Jan 27 2026
    It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: UK looks at starting universal T1D screening, Dexcom's CEO mentions a new product, bariatric sugery vs GLP medications, FDA approves update to prescribing info for inhaled insulin, miscroplastic and diabetes link studied, and more! Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom T1D Screening info All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Episode transcription with links: (Stacey Track) Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bringing you the top diabetes stories and headlines happening now. We are less than one month from our first MNO of 2026. Please join us in Silver Spring MD Feb 20 and 21. It's going to be amazing. We're going to Nashville next March 6-7 and we're going to have a great event a Club 1921 we just added on Thursday March 5th for health care providers and patient leaders. All the info is over at diabetes-connetionss.com events/ Okay.. our top story this week: XX All UK children could be offered screening for type 1 diabetes using a simple finger-prick blood test, say researchers who have been running a large study. This is the ELSA study - Early Surveillance for Autoimmune diabetes, a first of its kind UK study. They tested blood samples from 17,931 children aged 3-13 for autoantibodies, markers of type 1 diabetes that can appear years before symptoms. Families of children found to have early-stage type 1 diabetes received tailored education and ongoing support to prepare for the eventual onset of type 1 diabetes symptoms and to ensure insulin therapy can begin promptly when needed, reducing the chances of needing emergency treatment. Those with one autoantibody also received ongoing support and monitoring. Some families were also offered teplizumab, the first ever immunotherapy for type 1 diabetes, which can delay the need for insulin by around three years in people with early-stage type 1 diabetes. The second phase has launched and will expand screening to all children in the UK aged 2-17 years, with a focus on younger children (2-3 years) and older teenagers (14-17 years). The research team aims to recruit 30,000 additional children across these new age groups. ELSA 2 will assess how screening can be scaled across the NHS and evaluate its cost-effectiveness. https://www.birmingham.ac.uk/news/2026/childhood-type-1-diabetes-screening-is-effective-and-could-prevent-thousands-of-emergency-diagnoses XX At the J.P. Morgan Healthcare Conference Dexcom CEO Jake Leach says they're going to launch a new product outside the US. I'll link up that interview, The full quote: "When you look at the outside the U.S., there are a lot of structures that are tiered. Patients have access to different types of products, so we've got a new one that we want to introduce that will add flexibility there. It's based on the G7 platform, just like Dexcom ONE+, but it has a unique experience that's tailored for a subset of users that, today, don't have access to Dexcom." Your guess is as good as mine, but sounds more like a pricing or ordering issue than a new bit of hardware or software. Dexcom will also bring Stelo to some international markets this year. And plans a new mobile app experience for the wearable biosensor meant for people who don't dose insulin. Leach also says G8 will be much smaller and with more capability. but is a few years away. https://www.drugdeliverybusiness.com/dexcom-ceo-jake-leach-2026-roadmap-jpm/ XX A new international consensus statement provides guidance for the use of diabetes technology during pregnancy for women with type 1 diabetes (T1D), type 2 diabetes (T2D), or gestational diabetes (GD). Organized by the diaTribe Foundation, the document was based on evidence where available, as well as opinion from an international group of experts in endocrinology, diabetes technology, and obstetrics & gynecology, among others. This is the first set of recommendations specifically addressing the use of diabetes technology in pregnancy – and we'll link it up. https://www.medscape.com/viewarticle/new-consensus-statement-addresses-diabetes-tech-pregnancy-2026a100020d XX Bariatric surgery beats GLP-1s for type 2 diabetes across income levels. This study was published this month, looking at nearly 300 patients are 4 medical centers. Success here is measured by lower ...
    Afficher plus Afficher moins
    12 min
  • Chris Dunn got screened for her kids, turns out SHE has type 1 diabetes

    Chris Dunn got screened for her kids, turns out SHE has type 1 diabetes
    Jan 19 2026

    Imagine getting your kids screened for T1D and agreeing to do it yourself, just to set a good example, and then your test is the one that comes back with type 1!

    That's exactly what happened to Chris Dunn. She was positive for all of the autoantibodies and has since been treated with Tzield, the medication shown to delay the onset.

    We're talking to her about all of that, what the treatment is actually like, how she's doing since and what her family thinks of the whole thing.

    This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.

    Join us for an All Things Camp webinar TONIGHT 1/20 8pm ET

    Announcing Community Commericals! Learn how to get your message on the show here.

    Learn more about studies and research at Thrivable here

    Please visit our Sponsors & Partners - they help make the show possible!

    Omnipod - Simplify Life

    All about Dexcom

    All about VIVI Cap to protect your insulin from extreme temperatures

    The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
    Sign up for our newsletter here

    Here's where to find us:
    Facebook (Group)
    Facebook (Page)
    Instagram
    Check out Stacey's books!

    Learn more about everything at our home page www.diabetes-connections.com

    Afficher plus Afficher moins
    34 min
  • In the News... New islets study, Tzield for babies, MiniMed Go approved, Civica insulin launched, and more!

    In the News... New islets study, Tzield for babies, MiniMed Go approved, Civica insulin launched, and more!
    Jan 13 2026
    It's In the News... the top diabetes stories and headlines happening now! Top stories this week include: new islet encapsulation trial, FDA agrees to review Tzield for babies and approves the MiniMed Go, Civica releases it's version of Lantus, Eversense launches with a pump partner, scholarship for college students with diabetes and more! Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life All about Dexcom Screen it Like You Mean It All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Episode transcript: Welcome! This is an In the News episode.. we're doing things a little differently this year, but we are still bringing you the top diabetes stories and headlines happening now. We are rotating these shorter episodes with our longer, interview episodes.. but all on Tuesdays now. And that's why you'll hear ads on the in the news episodes. My usual disclaimer – we believe in the products advertised here but no one tells me what stories to run or what to say – the commercials are separate from the news. I know most podcasters don't do disclaimers anymore, but I come from traditional broadcasting and it's still important to me. Okay.. our top story this week: XX Positive results for a phase 1 clinical trial of encapsulated islets in people with type 1 from Encellin. This first-in-human trial is assessing (1) safety and adverse events, (2) cell survival within the device, and (3) fibrosis, or scarring, around the implants. As planned, ENCRT devices were removed from the initial five participants after 4 months of implantation. Analysis of the removed devices show: minimal to no fibrosis (formation of scar tissue around the device); robust formation of blood vessels around the device; viable islets inside the device. These results indicate that the device has the potential to host islet cells while maintaining sufficient oxygen and nutrient flow for the cells to work effectively. Breakthrough T1D's Role: Encellin's technology was originally developed within the Lab of Dr. Tejal Desai (University of California San Francisco) with funding from Breakthrough T1D, which was crucial in the formation of Encellin as a company and attracting subsequent venture capital. https://breakthrought1d.ca/cell-therapy-trial-encellins-device-delivers-promising-early-results/ XX The US Food and Drug Administration has accepted Tzield for priority review to expand the current age indication from eight years and above, to as young as one year old and above to delay the onset of stage 3 type 1 diabetes (T1D) in patients diagnosed with stage 2 T1D. The target action date for the FDA decision is April 29, 2026. "This priority review emphasizes the urgent need for innovative therapies like Tzield which has the potential to prevent the natural progression of T1D by delaying the loss of endogenous insulin production. This might be particularly significant in this young population, as it is well documented that the autoimmune attack that drives this disease in many cases, begins, early in life," said Christopher Corsico, Global Head of Development at Sanofi. "If approved, Tzield could represent an important advance for delaying the onset of stage 3 type 1 diabetes in early childhood, which would benefit patients and caregivers alike." Interim data for the PETITE-T1D phase 4 study was presented at the 51st Annual Conference of the International Society for Pediatric and Adolescent Diabetes and simultaneously published in Diabetologia. Priority review is given to regulatory applications seeking approval for therapies that have the potential to provide significant improvements in the treatment, diagnosis, or prevention of serious conditions. The safety and efficacy of Tzield in the PETITE-T1D population has not been approved by any regulatory authority. https://www.globenewswire.com/news-release/2026/01/05/3212420/0/en/Press-Release-Sanofi-s-Tzield-accepted-for-priority-review-in-the-US-for-young-children-with-stage-2-type-1-diabetes.html XX Sanofi said the U.S. Food and Drug Administration accepted a priority review to potentially expand the current age range for its Tzield type-1 diabetes drug to include children as young as one year old. The French pharmaceutical company said Monday that the FDA's review could amend the lower end of the range for ...
    Afficher plus Afficher moins
    12 min
  • GLP-1s for Type 1 Diabetes: Are We There Yet? With Dr. Cecilia Low Wang

    GLP-1s for Type 1 Diabetes: Are We There Yet? With Dr. Cecilia Low Wang
    Jan 7 2026

    One of the sure-thing top stories of 2026 will be GLP1s, but will we see more studies and even approval for treating type 1 with these medications?

    We're talking about Ozempic, Mounjaro and the next versions like Retatrutide - that are just around the corner. I'm talking to Dr. Cecelia Lo Wong, a diabetologist at the University of Colorado whose been on the front lines of this conversation for years, including serving on FDA advisory committees.

    This is a wide ranging interview - we also talk about the growing needs of older adults with type 1 diabetes, how kidney and cardiovascular risk guidelines are evolving, and why managing diabetes in the hospital can still be such a challenge.

    This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.

    This week's Community Commercial is from Lisa Katzenberger, the author of "It Belongs to the World," a children's book version of the story of Frederick Banting and the discovery of insulin. Learn more about this book here

    Announcing Community Commericals! Learn how to get your message on the show here.

    Learn more about studies and research at Thrivable here

    Please visit our Sponsors & Partners - they help make the show possible!

    Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com)

    Omnipod - Simplify Life

    All about Dexcom

    All about VIVI Cap to protect your insulin from extreme temperatures

    The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
    Sign up for our newsletter here

    Here's where to find us:
    Facebook (Group)
    Facebook (Page)
    Instagram
    Check out Stacey's books!

    Learn more about everything at our home page www.diabetes-connections.com

    Afficher plus Afficher moins
    38 min
  • In the News PLUS our 2026 Predictions

    In the News PLUS our 2026 Predictions
    Jan 2 2026

    It's In the News.. a look at the top headlines and stories in the diabetes community. This week we're also making predictions for diabetes news in 2026!

    This week's top stories: statins and type 2, big results from Lilly's newest weight loss drug, MiniMed IPO, Tandem app update, and more!

    Predicitons include thouhts around: continuous ketone monitoring, noninvasive gucose moniotring, inhalable insulin for kids, GLP1 backlash, A1 slop in diabetes mom groups and more!

    Announcing Community Commericals! Learn how to get your message on the show here.

    Learn more about studies and research at Thrivable here

    Please visit our Sponsors & Partners - they help make the show possible!

    Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com)

    Omnipod - Simplify Life

    All about Dexcom

    All about VIVI Cap to protect your insulin from extreme temperatures

    The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
    Sign up for our newsletter here

    Here's where to find us:
    Facebook (Group)
    Facebook (Page)
    Instagram
    Check out Stacey's books!

    Learn more about everything at our home page www.diabetes-connections.com

    Afficher plus Afficher moins
    14 min
  • Looking back on 2025: Hype, hope and what really matters, with Neil Greathouse

    Looking back on 2025: Hype, hope and what really matters, with Neil Greathouse
    Dec 30 2025

    This week on Diabetes Connections, a conversation about what really matters in diabetes. We're talking about the top stories of 2025, the hype that didn't happen, some trends for 2026, what community can accomplish, and what LeBron James has to do with all of this. We also get personal – because I'm being interviewed by the wonderful Neil Greathouse, host of Your Best T1D life, and so much more.

    This episode contains a replay of Your Best T1D Year. Check out Neil's great podcast!

    This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.

    Announcing Community Commericals! Learn how to get your message on the show here.

    Learn more about studies and research at Thrivable here

    Please visit our Sponsors & Partners - they help make the show possible!

    Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com)

    Omnipod - Simplify Life

    All about Dexcom

    All about VIVI Cap to protect your insulin from extreme temperatures


    The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
    Sign up for our newsletter here


    Here's where to find us:
    Facebook (Group)
    Facebook (Page)
    Instagram
    Check out Stacey's books!


    Learn more about everything at our home page www.diabetes-connections.com

    Afficher plus Afficher moins
    56 min
  • Do We Need an At-Home A1C Test in the Age of CGM? Orange Biomed Says Yes

    Do We Need an At-Home A1C Test in the Age of CGM? Orange Biomed Says Yes
    Dec 26 2025
    Making the case for a better at home A1C test. Orange Biomed is developing a compact, one-drop, at-home A1C testing device they say could make frequent A1C checks easier and more accessible than ever. They're passionate about closing the gap for people who struggle to get to clinics regularly… and the research they share is compelling: four A1C tests a year can lead to a nearly 4% reduction in A1C levels. We'll talk about why more frequent A1C monitoring matters—even in the era of continuous glucose monitoring—how their new device works, and what early clinical trial results look like. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. More about Orange BioMed here Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Episode transcript: Stacey Simms 00:05 Today on diabetes connections, making the case for a better at home A1C test. Orange biomed is developing a compact, one drop device that they say could make frequent A1C checks easier and more accessible. They're sharing research that four A1C tests a year can lead to a nearly 4% reduction in A1C levels, but they say a lot of people can't get to the clinic that much. We'll talk about why this matters, even in the era of CGM, how the device works and what the early clinical trial results look like. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your healthcare provider. Welcome to a bonus episode of diabetes connections. I hope your December is going well and that you know somehow you're able to take some time for yourself in the middle of all the holiday rushing around this time of year can be magical and stressful and exhausting and wonderful, and you know, all the things. And it's the same thing over here, super busy getting all this stuff done before the end of the year. Love it. But, you know, getting podcast episodes out, writing all the things we write and planning for next year, as they say, We're staying booked and busy. But quick behind the scenes here to better explain this episode, I taped this interview way back over the summer during the ADA Scientific Sessions conference. I had some technical problems. I actually thought I lost this interview. There were two interviews that seemed to have gone missing. We're going to air the other one very soon. But thankfully, I do have backups upon backups. So all the info that you're going to hear today is still relevant. This product, a small A1C test, is still in development. The only dated bit is about their follow up event that took place in August. Orange Biomed was launched in 2021 in South Korea, with its US headquarters in Providence, Rhode Island. Its founders are two Duke University alums, and they're my guests, CEO Yeaseul Park and Co-President Unghyeon Ko, We are also joined by Janice Dru-Bennett. She is a senior advisor at the company. Now, English is not the first language of two of these three speakers. This is a good time to remind you that most podcasting platforms have pretty good transcription services these days, especially Apple, I think they have a fantastic real time transcription service for podcasts that has been impressive to me in how they translate diabetes language. They're getting better at it. But I am also going to put a transcript of the interview in the show notes, which I don't normally do because the podcast services have gotten so good at it, but I think it could be helpful for at least a few of you out there. Okay, here is my conversation from the floor of ADA from the team at Orange biomed. Yeaseul Park, Janice Drew Bennett and Dr Ko, Welcome to diabetes connections. I can't say live from ADA, because we're taping this to air later, but you're all there. Thank you so much for joining Yeaseul Park 03:08 me. Yes, thank you. We're 03:10 excited to be here. Oh Stacey Simms 03:11 my goodness. Can I ask first, how is the trip? I mean, yes, let me ask you. You guys came a long way. Yeaseul Park 03:17 Yeah, it was 13 hours from Korea. But it's I'm so excited, because this event is really one of the times, and this is actually our third time attending ADA. Stacey Simms 03...
    Afficher plus Afficher moins
    23 min
  • She Turned Her Glucose Data Into Art. Could it Change How People See Diabetes?

    She Turned Her Glucose Data Into Art. Could it Change How People See Diabetes?
    Dec 23 2025

    What if your glucose graph became a tangible piece of art? Something you could pring out and put on your water bottle or the back of your laptop. I've seen this in person and it makes a big impact on people.

    This week I'm talking to Krista Shenaman about making this type of art, her journey with type 2 – and it's been a journey, she took a "record breaking" 28 day walk after her diagnosis.. – why she thinks its helpful to look at data in a new way and more.

    Full disclosure: We recorded this interview way back in 2024! Technical issues and thought it was lost, but we found it.

    This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.

    Announcing Community Commericals! Learn how to get your message on the show here.

    Learn more about studies and research at Thrivable here

    Please visit our Sponsors & Partners - they help make the show possible!

    Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com)

    Omnipod - Simplify Life

    Learn about Dexcom

    Check out VIVI Cap to protect your insulin from extreme temperatures

    The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:

    Sign up for our newsletter here

    Here's where to find us:

    Facebook (Group)

    Facebook (Page)

    Instagram

    Check out Stacey's books!

    Learn more about everything at our home page www.diabetes-connections.com

    Reach out with questions or comments: info@diabetes-connections.
    Afficher plus Afficher moins
    27 min